In consultation with a number of key stakeholders, KAMSC and KHR have developed a standard drug list for use in the Kimberley, the first edition being published in November 2005.
This standard drug list is largely defined by best practice guidelines and is intended to be used by Aboriginal community controlled health services and remote government clinics. It is also intended to be reflected in hospital imprest systems. It is hoped that this process of drug rationalization promotes consistency in care across health services and consequently, have widespread benefits for both clinicians and patients.
In order to establish a regional consensus, the first stage of development involved circulation of a comprehensive drug list to Kimberley clinicians. The drug list included therapeutic classes relevant to the health priorities of the Kimberley population. Clinicians were asked to select their preferences in each therapeutic class and provide rationale for these preferences.
A 3-part format for the standard drug list was established as follows:
This list consists of drugs that the steering committee recommends should be easily accessible to the Kimberley population and hence, included in all clinic medication imprests.
This list consists of drugs that should be able to be accessed across the Kimberley, but will not be required by all clinics.
Therefore, it is at the discretion of the senior clinicians as to whether or not these drugs are included on the clinics imprest. Drugs on the supplementary list are included for specific indications.
A KSDL Review Committee has been established to facilitate the updating and ongoing maintenance of this standard list. The committee meets once a year to review any new drugs which have been added to the PBS, new clinical data that has been reported, and also to review any KSDL modification request forms submitted by clinicians.
- Evidence based medicine/clinical trial data
- Regional preferences
- PBS indications and authority status (if applicable)
- Drug costs
- Side Effect Profile/Interactions
- Patient Compliance
The KSDL is a constant work in progress, and will be reviewed annually by the KSDL Review Committee. Please review the Summary Table for the most recent changes to the KSDL.
For further information, please refer to the minutes of the meeting which was held on September 9th 2010.
WACHS Regional Pharmacist on (08) 9194 2000